Juan Jose Fung, Principal Scientist, at GPCR Therapeutics.

October 2022 Genome-scale CRISPR screening reveals that C3aR signaling is critical for rapid capture of fungi by macrophages "The fungal pathogen Histoplasma capsulatum (Hc) invades, replicates within, and destroys and release of small peptide fragments such as C3a, a role for C3aR in macrophage interactions with fungi phagocytosis of bacteria and latex beads, it is critical for optimal macrophage capture of pathogenic fungi Hc-macrophage interactions and uncover a novel and specific role for C3aR in macrophage recognition of fungi

.- Jan Steyaert , scientific director of the VIB-VUB Center for Structural Biology , Vlaams Instituut Jan Steyaert will be presented with the Gabbay Award at Brandeis University on October 27 when he will

March 2022 Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced today the dosing

March 2022 Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment medicines targeting G-protein coupled receptors (GPCRs), today announced that the first subjects have been dosed

March 2022 ERNEST has established an Emergency Fund for Ukrainian researchers.

However, blind assessments of ligand pose quality and affinity prediction have thus far not provided Median ligand RMSD values for top-scored poses were 1.2 Å and 2.0 Å for self-docking and StateMatch/FunctionMatch

promoted to partner at Third Rock Ventures as the firm raised just over $600 million for its fourth fund Since then, Celniker has helped usher in an additional fund and headed a few startups as interim CEO. Coming on its 15th year, Third Rock Ventures announced its sixth fund today — and largest one by far That money has gone to some 60 biotechs, much of it as early funding."

In a LPS-induced lung inflammation model in mice, ACT-660602 led to significantly reduced recruitment of the CXCR3+ CD8+ T cell in the bronchoalveolar lavage compartment when administered orally at a dose

In addition, Structure Therapeutics has completed dosing in a single ascending dose (SAD) Phase 1 study

June 2022 "Published on juin 22, 2022 On June 22, 2022, Michel Bouvier , Chief Executive Officer of IRIC

ORs are highly expressed by olfactory sensory neurons of the nose where they are activated by different analyses, have indicated that OR genes are also expressed in non-olfactory tissues including the testis, lung epithelial cells proliferation via activation by β-ionone which initiates prostate cancer cell cycle arrest (Jones In non-small-cell lung cancer OR2J3 activation induced apoptosis and inhibited cell proliferation and

bioinformatics analysis to construct a risk model for ovarian cancer prognosis GprC of the nematode-trapping fungus Arthrobotrys flagrans activates mitochondria and reprograms fungal cells for nematode hunting Role and Biophysicists decipher functionality of adrenaline-binding receptor Tectonic plates more than $130m in new funding

cortisol excretion in the presence of sustained, disease-like ACTH concentrations in multiple-ascending dose

development, today announced that it has entered into a definitive agreement with Armistice Master Fund Additionally, Addex has agreed to issue to Armistice Capital unregistered pre-funded warrants to purchase up to 11,700,000 shares in the form of 1,950,000 ADSs (the “Unregistered Pre-Funded Warrants”) at a funded amount of $1.69 with $0.01 payable on exercise as well as unregistered warrants to purchase up in the form of 2,500,000 ADSs (the “Unregistered Warrants” and together with the “Unregistered Pre-Funded

9,230,772 shares in the form of 1,538,462 ADSs (the “Unregistered Warrants”), as well as unregistered pre-funded warrants to purchase up to 5,478,570 shares in the form of 913,095 ADSs (the “Unregistered Pre-Funded The Unregistered Pre-Funded Warrants have been funded to the amount of $6.49 with $0.01 payable on exercise

Such studies revealed that tissue response to a given dose of the hormone or its antagonist depends on

Ultimately this could lead to identification of new non-MOR targets that would allow for lower dose utilization

Complex in Stress and Anxiety Disorders GPCRs in Oncology and Immunology Exacerbating effects of single-dose by the American College of Clinical Pharmacology Sosei and Cancer Research UK announce first patient dosed

1984 (Cerione et al. 1984), where reconstitution of purified β2-adrenergic receptors from guinea pig lung of adjustability in terms of pharmacological effects, allowing for the administration of substantial doses

Cancer Research UK , a charity dedicated to funding lifesaving oncology research, spent £388 million Much of that funding is distributed to support third party research, but the group also does its own

The PVT appears to provide stimulus salience encoding in a dose- and NPS-dependent manner.

2022 Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund announced that the Company entered into a royalty-based financing with an affiliate of R-Bridge Healthcare Fund

Let's gather 'round for our weekly dose of GPCR News. Congratulations to our Dr. Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for

million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund million tranche from its royalty-based financing agreement with an affiliate of R-Bridge Healthcare Fund

immunothrombosis has become more relevant than ever, as a majority of COVID-19 patients display thrombi in the lung Furthermore, NETs can be found in the lung and other tissues and are associated with an increased mortality cytokine storm that potently activates neutrophils and leads to massive neutrophil infiltration into the lung

Pulmonary Fibrosis "Idiopathic pulmonary fibrosis (IPF) is a disease characterized by irreversible lung We demonstrate that OGR1 protein expression is significantly reduced in lung tissue from patients with

antibody mogamulizumab has also been approved in Japan and by the FDA for the treatment of mycosis fungoides molecular redundancy, pointing out that, in some cases, inappropriate target selection and insufficient dosing